← All trials
NCT07097831
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2025
- Primary completion
- Sep 30, 2025
- Completion date
- Sep 30, 2025
- First posted
- Jul 31, 2025
- Last posted
- Jul 31, 2025
- Enrollment
- 16
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.